IDEXX Laboratories (NASDAQ:IDXX) will release its quarterly earnings report on Monday, 2026-02-02. Here’s a brief overview for investors ahead of the announcement.
Analysts anticipate IDEXX Laboratories to report an earnings per share (EPS) of $2.94.
The market awaits IDEXX Laboratories’s announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It’s important for new investors to understand that guidance can be a significant driver of stock prices.
Performance in Previous Earnings
During the last quarter, the company reported an EPS beat by $0.08, leading to a 0.11% drop in the share price on the subsequent day.
Here’s a look at IDEXX Laboratories’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 3.14 | 3.3 | 2.85 | 2.40 |
| EPS Actual | 3.22 | 3.5 | 2.91 | 2.53 |
| Price Change % | 0.00 | -6.0 | 0.00 | -1.00 |
Market Performance of IDEXX Laboratories’s Stock
Shares of IDEXX Laboratories were trading at $676.71 as of January 29. Over the last 52-week period, shares are up 44.28%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analysts’ Take on IDEXX Laboratories
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding IDEXX Laboratories.
IDEXX Laboratories has received a total of 5 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $802.0, the consensus suggests a potential 16.61% upside.